Skip to main content

Immunogenicity of Therapeutic Proteins

Abstract

The use of proteins for medical applications has revolutionized therapies of many diseases/disorders that were often incurable with small-molecule medicines. However, since the first use of proteins as medicines, their immunogenicity has been a major problem. Over the years the quality and safety of therapeutic protein products have improved dramatically. Nevertheless, even the protein medicines of the newest generation may still cause adverse immunological events, posing a safety risk for patients and/or compromising their efficacy. Immunogenicity of therapeutic proteins is a complex, multifactorial phenomenon. In this chapter we summarize the current knowledge about immune mechanisms underlying the immunogenicity of therapeutic proteins and discuss influencing factors and clinical consequences of protein immunogenicity as well as strategies for immunogenicity assessment and mitigation.

Keywords

  • Aggregation
  • Anti-drug antibodies (ADA)
  • Formulation
  • Immunogenicity
  • Neutralizing antibodies
  • Tolerance

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-00710-2_7
  • Chapter length: 12 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   89.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-00710-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   119.99
Price excludes VAT (USA)
Figure 7.1
Figure 7.2
Figure 7.3

References

  • Aledort L (1994) Inhibitors in hemophilia patients: current status and management. Am J Hematol 47:208–217

    CAS  CrossRef  Google Scholar 

  • Antonelli G, Dianzani F (1999) Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 10:413–422

    CAS  PubMed  Google Scholar 

  • Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM (1993) The influence of antigen organization on B cell responsiveness. Science 262:1448–1451

    CAS  CrossRef  Google Scholar 

  • Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity. Clin Immunol 118:42–50

    CAS  CrossRef  Google Scholar 

  • Barnard JG, Babcock K, Carpenter JF (2013) Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. J Pharm Sci 102:915–928

    CAS  CrossRef  Google Scholar 

  • Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460–1468

    CAS  CrossRef  Google Scholar 

  • Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P (2004) Immunogenicity of interferon beta: differences among products. J Neurol 251:II15–II24

    CrossRef  Google Scholar 

  • Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S (2015) Immunogenicity to infliximab is associated with HLA-DRB1. Gut 64:1344–1345

    CAS  CrossRef  Google Scholar 

  • Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T (2015) Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 418:29–38

    CAS  CrossRef  Google Scholar 

  • Brandse JF, Mathôt RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, Rietdijk S, Löwenberg M, Ponsioen CY, Singh S, van den Brink GR, D’Haens GR (2016) Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 14:251–258

    CAS  CrossRef  Google Scholar 

  • Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, Rup B, Jiskoot W (2013) Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res 30:1719–1728

    CAS  CrossRef  Google Scholar 

  • Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475

    CAS  CrossRef  Google Scholar 

  • Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 358:1109–1117

    CAS  CrossRef  Google Scholar 

  • Cousens L, Najafian N, Martin WD, De Groot AS (2014) Tregitope: immunomodulation powerhouse. Hum Immunol 75:1139–1146

    CAS  CrossRef  Google Scholar 

  • de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU (2015) Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediat Inflamm 2015:1–11

    CrossRef  Google Scholar 

  • Fakharzadeh SS, Kazazian HH Jr (2000) Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26:167–172

    CAS  CrossRef  Google Scholar 

  • Fijal B, Ricci D, Vercammen E, Palmer PA, Fotiou F, Fife D, Lindholm A, Broderick E, Francke S, Wu X, Colaianne J, Cohen N (2008) Case–control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. Pharmacogenomics 9:157–167

    CAS  CrossRef  Google Scholar 

  • Finco D, Baltrukonis D, Clements-Egan A, Delaria K, Gunn GR 3rd, Lowe J, Maia M, Wong T (2011) Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J Pharm Biomed Anal 54:351–358

    CAS  CrossRef  Google Scholar 

  • Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS (2007) Immunological responses to exogenous insulin. Endocr Rev 28:625–652

    CAS  CrossRef  Google Scholar 

  • Food and Drug Administration (2002) Adalimumab. 2002. Pharmacology reviews: adalimumab product approval information—licensing action. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110TOC.cfm. Accessed 4 Nov 2017

  • Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C, Xue L (2016) Pre-existing antibody: biotherapeutic modality-based review. AAPS J 18:311–320

    CAS  CrossRef  Google Scholar 

  • Griswold KE, Bailey-Kellogg C (2016) Design and engineering of deimmunized biotherapeutics. Curr Opin Struct Biol 39:79–88

    CAS  CrossRef  Google Scholar 

  • Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, Jawa V (2017) Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J Pharm Sci 106:2946–2954

    CAS  CrossRef  Google Scholar 

  • Han PD, Cohen RD (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64:1767–1777

    CAS  CrossRef  Google Scholar 

  • Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The Immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256–265

    CrossRef  Google Scholar 

  • Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897–903

    CAS  CrossRef  Google Scholar 

  • Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS (2013) T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol 149:534–555

    CAS  CrossRef  Google Scholar 

  • Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, Joubert MK, Jawa V, Narhi LO (2016) Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci 105:1567–1575

    CAS  CrossRef  Google Scholar 

  • Kijanka G, Jiskoot W, Sauerborn M, Schellekens H, Brinks V (2012) Immunogenicity of therapeutic proteins in pharmaceutical formulation development of peptides and proteins. CRC Press, Boca Raton, pp 297–322

    Google Scholar 

  • Krishna M, Palme H, Duo J, Lin Z, Corbett M, Dodge R, Piccoli S, Myler H, Pillutla R, Desilva B (2015) Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples. Bioanalysis 7:1869–1883

    CAS  CrossRef  Google Scholar 

  • Liu L (2015) Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104:1866–1884

    CAS  CrossRef  Google Scholar 

  • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932–1939

    CAS  CrossRef  Google Scholar 

  • Malucchi S, Bertolotto A (2008) Clinical aspects of immunogenicity to biopharmaceuticals. Immunog Biopharm 47:27–56

    CrossRef  Google Scholar 

  • Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1–16

    CAS  CrossRef  Google Scholar 

  • Moore WV, Leppert P (1980) Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691–697

    CAS  CrossRef  Google Scholar 

  • Moss AC, Brinks V, Carpenter JF (2013) Review article: Immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther 38:1188–1197

    CAS  CrossRef  Google Scholar 

  • Oldenburg J, Lacroix-Desmazes S, Lillicrap D (2015) Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating Factor VIII immunogenicity. Haematologica 100:149–156

    CAS  CrossRef  Google Scholar 

  • Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P (2001) Interferon-beta (INF-Beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12:56–61

    CAS  PubMed  Google Scholar 

  • Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh O, Jootar S, Intarakumthornchai T, Pongskul C, Prasithsirikul W, Achavanuntakul B, Ruangkarnchanasetr P, Laohavinij S, Eiam-Ong S (2009) The association of anti-R-HuEpo-associated pure Red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol Dial Transplant 24:1545–1549

    CAS  CrossRef  Google Scholar 

  • Prümmer O (1997) Treatment-induced antibodies to interleukin-2. Biotherapy 10:15–24

    CrossRef  Google Scholar 

  • Richter WF, Bhansali SG, Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following sc administration. AAPS J 14:559–570

    CAS  CrossRef  Google Scholar 

  • Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose Frequency, and route of administration. Ann Neurol 48:706–712

    CAS  CrossRef  Google Scholar 

  • Rougeot C, Marchand PM, Dray F, Girard F, Job JC, Pierson M, Ponte C, Rochiccioli P, Rappaport R (1991) Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res 35:76–81

    CAS  CrossRef  Google Scholar 

  • Ryff JC (1997) Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interf Cytokine Res 17:S29–S33

    CAS  Google Scholar 

  • Schellekens H (2002a) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457–462

    CAS  CrossRef  Google Scholar 

  • Schellekens H (2002b) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720–1740

    CAS  CrossRef  Google Scholar 

  • Schellekens H, Casadevall N (2004) Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251:II4–II9

    CrossRef  Google Scholar 

  • Schellekens H, Jiskoot W (2006) Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol 3:123–130

    CAS  CrossRef  Google Scholar 

  • Schellekens H, Hennink WE, Brinks V (2013) The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 30:1729–1734

    CAS  CrossRef  Google Scholar 

  • Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267–1281

    CAS  CrossRef  Google Scholar 

  • Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S (2014) Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations. AAPS J 16:658–673

    CAS  CrossRef  Google Scholar 

  • Singh SK (2011) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100:354–387

    CAS  CrossRef  Google Scholar 

  • van Beers MM, Jiskoot W, Schellekens H (2010) On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interf Cytokine Res 30:767–775

    CrossRef  Google Scholar 

  • van de Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108:962–971

    CAS  CrossRef  Google Scholar 

  • van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T (2015a) The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 74:311–314

    CrossRef  Google Scholar 

  • van Schie KA, Wolbink GJ, Rispens T (2015b) Cross-reactive and pre-existing antibodies to therapeutic antibodies. Effects on treatment and immunogenicity. MAbs 7:662–671

    CrossRef  Google Scholar 

  • van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T (2017) Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: the immune response to antibody therapeutics preferentially targets the Antigen-binding site. J Allergy Clin Immunol 139:1035–1037

    CrossRef  Google Scholar 

  • van Schouwenburg PA, Rispens T, Wolbink GJ (2013a) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9:164–172

    CrossRef  Google Scholar 

  • van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013b) Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 72:1680–1686

    CrossRef  Google Scholar 

  • Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADA) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72:165–178

    CAS  CrossRef  Google Scholar 

  • Weigle WO (1971) Recent observations and concepts in immunological unresponsiveness and autoimmunity. Clin Exp Immunol 9:437–447

    CAS  PubMed  PubMed Central  Google Scholar 

  • Xue L, Rup B (2013) Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J 15:893–896

    CAS  CrossRef  Google Scholar 

Suggested Reading

  • Brinks V, Jiskoot W, Schellekens H (2011) Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 28:2379–2385

    CAS  CrossRef  Google Scholar 

  • Filipe V, Hawe A, Schellekens H, Jiskoot W (2010) Aggregation and immunogenicity of therapeutic proteins. In: Wang W, Robert C (eds) Aggregation of therapeutic proteins. Wiley, Hoboken

    CrossRef  Google Scholar 

  • Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W (2007) Immunogenicity of therapeutic proteins. In: Gad SC (ed) Handbook of pharmaceutical biotechnology. Wiley, Hoboken, pp 911–931

    Google Scholar 

  • Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM (2016) Immunogenicity of therapeutic protein aggregates. J Pharm Sci 105:417–430

    CAS  CrossRef  Google Scholar 

  • Schellekens H, Crommelin D, Jiskoot W (2007) Immunogenicity of antibody therapeutics. In: Dübel S (ed) Handbook of therapeutic antibodies. Wiley, Weinheim, pp 267–276

    CrossRef  Google Scholar 

  • Schellekens H (2010) The immunogenicity of therapeutic proteins. Discov Med 9:560–564

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wim Jiskoot .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Jiskoot, W., Rispens, T., Kijanka, G. (2019). Immunogenicity of Therapeutic Proteins. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_7

Download citation